| Assessment Status |
Rapid Review Complete |
| HTA ID |
25067 |
| Drug |
Donanemab |
| Brand |
Kisunla® |
| Indication |
Donanemab (Kisunla™) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology. |
| Rapid review commissioned |
12/11/2025 |
| Rapid review completed |
11/12/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of donanemab compared with the current standard of care. |
